Table 4.
Association of Anticoagulant Treatment Strategies and Patient Characteristics With In-Hospital Bleeding Events
| OR (95% CI) | |
|---|---|
| Anticoagulants (REF: UFH only) | |
| UFH+LMWH | 0.98 (0.82 to 1.17) |
| LMWH only | 0.84 (0.71 to 1.00) |
| Bivalirudin (any) | 0.84 (0.76 to 0.93) |
| Patient factors | |
| Age (REF ≥75 years) | |
| 18 to <55 | 0.45 (0.40 to 0.51) |
| 55 to <65 | 0.56 (0.50 to 0.63) |
| 65 to <75 | 0.78 (0.70 to 0.87) |
| Female | 1.51 (1.39 to 1.65) |
| Hypertension | 0.87 (0.79 to 0.95) |
| Congestive heart failure | 3.77 (2.46 to 5.77) |
| Peripheral vascular disease | 1.37 (1.22 to 1.55) |
| Diabetes with complications | 1.22 (1.02 to 1.45) |
| Renal failure | 1.64 (1.46 to 1.84) |
| Chronic pulmonary disease | 1.53 (1.39 to 1.69) |
| Liver disease | 1.81 (1.34 to 2.44) |
| Weight loss | 2.48 (2.04 to 3.01) |
| Deficiency anemia | 1.17 (1.04 to 1.30) |
| Chronic blood loss anemia | 6.64 (5.25 to 8.40) |
| Coagulopathy | 2.35 (2.04 to 2.71) |
| Fluid and electrolyte disorder | 2.43 (2.22 to 2.67) |
| Metastatic cancer | 1.81 (1.20 to 2.72) |
| Solid tumor without metastasis | 1.88 (1.42 to 2.49) |
| Paralysis | 1.64 (1.22 to 2.20) |
| ST-elevation MI | 1.24 (1.14 to 1.36) |
| Glycoprotein IIb/IIIa inhibitor | 1.60 (1.45 to 1.76) |
c-index=0.76. LMWH indicates low-molecular-weight heparin; MI, myocardial infarction; OR, odds ratio; UFH, unfractionated heparin.